In pathogenesis of ER-positive breast cancer, SPHK1/S1P axis and estrogen receptor signaling have been known to interact with one another, leading to enhanced tumor growth and therapy resistance (Sukocheva and Wadham, 2014). Here, SPHK1 is linked to neoplasm.